Mitsu Chem Plast has allotted 10 lakh fully convertible warrants to promoters and non-promoter entities at Rs 151 per warrant, raising Rs 15.1 crore in total value. The company has received the mandatory 25% upfront payment. These warrants are convertible into equity shares within 18 months, providing the company with a long-term capital infusion path while signalling promoter confidence.
Mitsu Chem Plast Allots 10 Lakh Convertible Warrants
The company has raised 25% of the Rs 15.1 crore total issue value as upfront payment.
Ten lakh warrants have been issued at a price of Rs 151 per warrant.
Reader Takeaway: Promoter-backed capital infusion provides immediate liquidity but may cause future equity dilution upon warrant conversion.
What just happened
Mitsu Chem Plast Ltd has officially allotted 10,00,000 fully convertible warrants to a mix of promoters and a non-promoter entity. The issuance was priced at Rs 151 per warrant, comprising a face value of Rs 10 and a premium of Rs 141. The company has successfully collected the required 25% upfront payment, amounting to Rs 3.775 crore. This process follows formal shareholder approval granted in September 2026 and BSE in-principle approval received earlier in October.
Why this matters
For retail investors, this allotment represents a strategic capital-raising exercise. The upfront cash provides the company with immediate working capital or funds for future growth. Because the warrants are convertible into equity shares within 18 months, the company ensures a structured approach to increasing its equity base. Existing shareholders should note that while the share capital remains unchanged today, the future exercise of these warrants will lead to an expansion of total equity and potential dilution.
Transaction Details
The allotment includes 4,75,000 warrants to promoter Manish Mavji Dedhia, 3,25,000 warrants to promoter Sanjay Mavji Dedhia, and 2,00,000 warrants to non-promoter entity Rikhav Securities Limited. Each allottee has met the 25% upfront payment requirement as mandated by SEBI guidelines.
Risks to watch
The primary consideration for investors is the dilution impact. When the warrant holders eventually exercise their option to convert, the company's total outstanding equity shares will increase. Investors should track the company’s capital allocation strategy regarding how these funds are utilized to drive operational performance and justify the eventual expansion of equity.